Loading...

INBS INTELLIGENT BIO SOLUTIONS INC Capital Structure Changes 8-K Filing

NTLL

NBS

INTELLIGENT BIO SOLUTIONS INC

(INBS)

2024 8-K

Stock Split Announcement

Investor Presentation

Share Issuance Approval

Financial Results Announced

Preliminary Revenue Results

New Customer Accounts

Annual Meeting Results

FDA Update Announcement

Warrant Extension

Financial Results Announcement

Financial Statements

Pre-Market Approval

Rights Offerings

Clinical Trials

Global Distribution Agreement

New Product Launches

Appointments, Resignations

Market Expansion

Appointing Directors

Patent Announcement

Annual Meeting Notice

Financial Results

Expansion Strategy

Financial Results

Contract Adoption

Partnership Announcement

Investor Presentation

Product Study Success

FDA Submission Results

Financial Results

Revenue Announcement

FDA Testing Success

Financial Results

Revenue Announcement

FDA Submission Progress

Employee Growth

Milestone Achievement

Drug Testing Demand

Investment in Exclusive Dis...

Salary Increase

Management Changes

Resignation and Appointment...

Regulation FD Disclosure

Exhibition Announcement

Financial Results Announcement

Financial Results

Intellectual Property Portf...

Regulation FD Disclosure

Securities Purchase Agreement

Agreements with C2C Advisor...

Partnership Announcement

Compliance with Nasdaq List...

Financial Results Announcement

Warrant Inducement Agreements

Financial Results

Investment Announcement

Reverse Stock Split

Accreditation Announcement

Nasdaq Compliance

Annual Meeting of Stockholders

Delisting Notice

Financial Results Announcement

Departure of Directors

Underwriting Agreement for ...

ISO 13485: 2016 Recertifica...

Debut of Drug Screening Sol...

Certificate of Elimination ...

Reorganizations

FDA Guidance for US Expansion

Resignation of Director

Convertible Loan Conversion...

Addition of Fentanyl to Lab...

Financial Results Announcement

Special Meeting Approval

Expansion and Investment

Investment in Drug Testing ...

Underwriting Agreement for ...

Compliance Regained

Financial Results Announcement

Long Term Incentive Plan Am...

Investment in Drug Testing ...

External Links:

Intelligent Bio Solutions Inc. disclosed initial results from its Pharmacokinetic study for FDA submission and raised approximately $250,802 from stock sales under an At The Market Offering Agreement.

AI Assistant

INTELLIGENT BIO SOLUTIONS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.